Histone deacetylases inhibitors as anti-angiogenic agents altering vascular endothelial growth factor signaling
The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
Angiogenesis is a complex biological process involving the coordinated modulation of many genes. Histone deacetylases (HDAC) are a growing family of enzymes that mediate the availability of chromatin to the transcriptional machinery. Trichostatin-A (TSA) and suberoylanilide hydroxamic acid (SAHA), two HDAC inhibitors known to relieve gene silencing, were evaluated as potential antiangiogenic agents. TSA and SAHA were shown to prevent vascular endothelial growth factor (VEGF)-stimulated human umbilical cord endothelial cells (HUVEC) from invading a type I collagen gel and forming capillary-like structures. SAHA and TSA inhibited the VEGF-induced formation of a CD31-positive capillary-like network in embryoid bodies and inhibited the VEGF-induced angiogenesis in the CAM assay. TSA also prevented, in a dose-response relationship, the sprouting of capillaries from rat aortic rings. TSA inhibited in a dose-dependent and reversible fashion the VEGF-induced expression of VEGF receptors, VEGFR1, VEGFR2, and neuropilin-1. TSA and SAHA upregulated the expression by HUVEC of semaphorin III, a recently described VEGF competitor, at both mRNA and protein levels. This effect was specific to endothelial cells and was not observed in human fibroblasts neither in vascular smooth muscle cells. These observations provide a conspicuous demonstration that HDAC inhibitors are potent anti-angiogenic factors altering VEGF signaling.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“inhibition of HDAC attenuates VEGF signalling, which is important for vascular morphogenesis and endothelial differentiation [195].”
From Transition from inflammation to proliferation: a critical step during wound healing (2016) · cites this paper as [195]
Citations
Cites
Vascular endothelial growth factor (VEGF) and its receptors
NEUFELD, G., COHEN, T., GENGRINOVITCH, S., & POLTORAK, Z. (1999) · The FASEB Journal · doi:10.1096/fasebj.13.1.9 · Cited by 3,483 · cited 7×
“…e ect of TSA on the phenotype of HUVEC was further evaluated by measuring the steady-state level of the mRNAs coding for the VEGF receptors, VEGFR1, its soluble form sVEGFR1, VEGFR2 (Neufeld et al., 1999), and the recently identi®ed co-receptor for VEGF165, neuropilin-1 (Miao et al., 1999).”
BackgroundInfluentialYoshida, M., Kijima, M., Akita, M., & Beppu, T. (1990) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)44885-x · Cited by 1,854
Histone acetylation and transcriptional regulatory mechanisms
Struhl, K. (1998) · Genes & Development · doi:10.1101/gad.12.5.599 · Cited by 1,815 · cited 4×
“HDAC have been associated with a repression of transcription (Struhl, 1998) and their inhibition should relieve gene silencing.”
BackgroundInfluentialAntiangiogenic therapy of experimental cancer does not induce acquired drug resistance
Boehm, T., Folkman, J., Browder, T., & O'Reilly, M. S. (1997) · Nature · doi:10.1038/37126 · Cited by 1,683 · cited 1×
“Antiangiogenic therapy of cancers o ers the possibility of a low toxicity treatment without acquisition of drug resistance due to the genetic stability, homogeneity and low mutational rate of endothelial cells (Boehm et al., 1997).”
BackgroundA class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases
Richon, V. M., Emiliani, S., Verdin, E., Webb, Y., Breslow, R., Rifkind, R. A., & Marks, P. A. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.6.3003 · Cited by 914 · cited 2×
“By using speci®c inhibitors, mainly TSA and SAHA (Yoshida et al., 1990; Richon et al., 1998) in di erent models based on in vitro, ex vivo and in vivo assays, we demonstrated that HDAC inhibition suppresses the spontaneous or VEGFinduced angiogenesis.”
BackgroundMethodSelf-citationHistone deacetylases induce angiogenesis by negative regulation of tumor suppressor genes
Kim, M. S., Kwon, H. J., Lee, Y. M., Baek, J. H., Jang, J.-E., Lee, S.-W., Moon, E.-J., Kim, H.-S., Lee, S.-K., Chung, H. Y., et al. (2001) · Nature Medicine · doi:10.1038/86507 · Cited by 731 · cited 7×
“At the time that we were preparing this manuscript, a study reporting the involvement of histone deacetylases in angiogenesis was published by Kim et al. (2001).”
BackgroundMethodInfluentialKijima, M., Yoshida, M., Sugita, K., Horinouchi, S., & Beppu, T. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)41547-5 · Cited by 514
Embryonic stem cells differentiate in vitro to endothelial cells through successive maturation steps
Vittet, D., Prandini, M., Berthier, R., Schweitzer, A., Martin-Sisteron, H., Uzan, G., & Dejana, E. (1996) · Blood · doi:10.1182/blood.v88.9.3424.bloodjournal8893424 · Cited by 472 · cited 1×
“Capillary-like structures formation was analysed by the expression of CD31 in whole mount immuno¯uorescence as reported by Vittet et al. (1996).”
MethodNeuropilin-1 Mediates Collapsin-1/Semaphorin III Inhibition of Endothelial Cell Motility
Miao, H.-Q., Soker, S., Feiner, L., Alonso, J. L., Raper, J. A., & Klagsbrun, M. (1999) · The Journal of Cell Biology · doi:10.1083/jcb.146.1.233 · Cited by 458 · cited 5×
“…e ect of TSA on the phenotype of HUVEC was further evaluated by measuring the steady-state level of the mRNAs coding for the VEGF receptors, VEGFR1, its soluble form sVEGFR1, VEGFR2 (Neufeld et al., 1999), and the recently identi®ed co-receptor for VEGF165, neuropilin-1 (Miao et al., 1999).”
BackgroundInfluentialDeroanne, C. (2001) · Cardiovascular Research · doi:10.1016/s0008-6363(00)00233-9 · Cited by 256 · cited 1×
“Culture medium, Oncogene HUVEC were induced to organize into a network of tube-like structures as described (Deroanne et al., 1996, 2001).”
MethodSelf-citation
Cited by
Anticancer activities of histone deacetylase inhibitors
Bolden, J. E., Peart, M. J., & Johnstone, R. W. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2133 · Cited by 2,919
Transition from inflammation to proliferation: a critical step during wound healing
Landén, N. X., Li, D., & Ståhle, M. (2016) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-016-2268-0 · Cited by 1,980
Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders
Falkenberg, K. J., & Johnstone, R. W. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4360 · Cited by 1,564
Histone deacetylase inhibitors: molecular mechanisms of action
Xu, W. S., Parmigiani, R. B., & Marks, P. A. (2007) · Oncogene · doi:10.1038/sj.onc.1210620 · Cited by 1,542
“TSA, vorinostat, FK228, butyrate and LAQ824 were found to repress angiogenesis in vitro and in vivo, and reduce expression of pro-angiogenesis factors, including HIF-1a and VEGF (Deroanne et al., 2002; Bolden et al., 2006; Liang et al., 2006).”
BackgroundInfluentialHistone Deacetylase Inhibitors as Anticancer Drugs
Eckschlager, T., Plch, J., Stiborova, M., & Hrabeta, J. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18071414 · Cited by 1,206
“In addition, HDAC inhibitors decrease the levels of the VEGF receptors in neuroblastoma cells [113].”
Background
Metadata
- Authors
- Deroanne, C. F., Bonjean, K., Servotte, S., Devy, L., Colige, A., Clausse, N., Blacher, S., Verdin, E., Foidart, J.-M., Nusgens, B. V., & Castronovo, V.
- Affiliations
- University of Liège (BE)
- University of California, San Francisco (US)
- Corresponding author
- Deroanne, Christophe F
- Venue
- Oncogene
- Published
- 2002-01-17
- Volume
- 21
- Issue
- 3
- Pages
- 427-436
- ISSN
- 0950-9232 (ISSN-L)
- 1476-5594
- OpenAlex
- W2031671750
- Cited by
- 400
- References
- 25
- Citations by year
- 2026: 5 · 2025: 7 · 2024: 6 · 2023: 6 · 2022: 9 · 2021: 24 · 2020: 11 · 2019: 16 · 2018: 10 · 2017: 18 · 2016: 18 · 2015: 18 · 2014: 20 · 2013: 15 · 2012: 27
- FWCI
- 5.44
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Oncogene (publishedVersion)
- PubMed (publishedVersion)
- Open Repository and Bibliography (University of Liège) (submittedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Histone Deacetylase Inhibitors Research
- Health Sciences › Medicine › Oncology › Lymphatic System and Diseases
- Keywords
- histone deacetylase inhibitors, trichostatin A, vorinostat, angiogenesis inhibitors, VEGF signaling, VEGF receptors, VEGFR1, VEGFR2, neuropilin-1, human umbilical vein endothelial cells, capillary formation, angiogenesis, chromatin remodeling
- MeSH terms
- Vorinostat, Animals, Aorta, Carrier Proteins, Cells, Cultured, Chick Embryo, Chorion, Endothelium, Vascular, Histone Deacetylases, Humans, Hydroxamic Acids, Lymphokines, Microscopy, Fluorescence, Microscopy, Phase-Contrast, Nerve Tissue Proteins, RNA, Messenger, RNA, Ribosomal, 28S, Umbilical Veins, Blotting, Western, Signal Transduction, Up-Regulation, Endothelial Growth Factors, Reverse Transcriptase Polymerase Chain Reaction, Angiogenesis Inhibitors, Semaphorin-3A, Vascular Endothelial Growth Factors, Vascular Endothelial Growth Factor A, Rats, Histone Deacetylase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Histone deacetylases inhibitors as anti-angiogenic agents altering vascular endothelial growth factor signaling. https://app.cochat.ai/papers/10.1038/sj.onc.1205108
- The paper
- Deroanne, C. F., Bonjean, K., Servotte, S., Devy, L., Colige, A., Clausse, N., Blacher, S., Verdin, E., Foidart, J.-M., Nusgens, B. V., & Castronovo, V. (2002). Histone deacetylases inhibitors as anti-angiogenic agents altering vascular endothelial growth factor signaling. Oncogene. https://doi.org/10.1038/sj.onc.1205108
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.